Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schneider–Gold, C.
Right arrow Articles by Toyka, K. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schneider–Gold, C.
Right arrow Articles by Toyka, K. V.
Related Collections
Right arrow All Neuromuscular Disease
Right arrow Muscle disease
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)

Neurology 2003;60:500-502
© 2003 American Academy of Neurology
Brief Communications

Creatine monohydrate in DM2/PROMM

A double-blind placebo-controlled clinical study

C. Schneider–Gold, MD, M. Beck, MD, C. Wessig, MD, A. George, MD, H. Kele, MD, K. Reiners, MD and K. V. Toyka, MD

From the Department of Neurology (Drs. Schneider–Gold, Beck, Wessig, George, Reiners, and Toyka), University of Würzburg; and Department of Clinical Neurophysiology (Dr. Kele), University of Göttingen, Germany.

Address correspondence and reprint requests to Dr. Christiane Schneider–Gold, Department of Neurology, University of Würzburg, Josef-Schneider Str. 11, 97080 Würzburg, Germany; e-mail: chris.schneider{at}mail.uni-wuerzburg.de

The efficacy and safety of creatine monohydrate (Cr) in patients with myotonic dystrophy type 2/proximal myotonic myopathy were studied in a small placebo-controlled double-blind trial. Twenty patients received either Cr or placebo for 3 months. After 3 months, there were no significant differences of muscle strength as assessed by hand-held dynamometry, testing of maximum grip strength, Medical Research Council scoring, and the Neuromuscular Symptom Score between the two groups. Some measures indicated trends toward mild improvement with Cr. Myalgia improved in two patients.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. A. Tarnopolsky, J. M. Bourgeois, R. Snow, S. Keys, B. D. Roy, J. M. Kwiecien, and J. Turnbull
Histological assessment of intermediate- and long-term creatine monohydrate supplementation in mice and rats
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2003; 285(4): R762 - R769.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.